← Oncology Approval Tracker

FDA DECISION ·

Blenrep

belantamab mafodotin-blmf · GlaxoSmithKline

Accelerated approvalNew therapyMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Indication withdrawn on Feb 6, 2023

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with relapsed or refractory multiple myeloma after at least four prior therapies, including an anti-CD38 antibody, a proteasome inhibitor and an immunomodulatory agent.

LAMPGEN ANALYSIS

Why it matters

Introduced a BCMA-targeted antibody-drug conjugate under accelerated approval; this original monotherapy indication was later withdrawn.

What research teams should watch

Coordinate eye examinations and distinguish this historical indication from later, separately approved regimens.

PRIMARY RECORDS

Sources